British biopharmaceutical company AstraZeneca has announced plans to invest $50 billion in the U.S. by 2030, as reported on Monday.
This major investment is set to generate tens of thousands of new, skilled jobs, both directly and indirectly. A significant part of this initiative includes a multi-billion dollar manufacturing facility proposed in Virginia. This facility aims to produce drugs for AstraZeneca’s weight management line, particularly oral GLP-1 medications. The company noted that this facility would represent the largest single manufacturing investment globally.
In a statement, AstraZeneca’s CEO, Pascal Soriot, expressed confidence in American innovation within the biopharmaceutical sector. He emphasized the company’s commitment to patients globally, especially in the U.S. Furthermore, he mentioned the collaborative efforts with Governor Youngkin’s team to make this substantial investment a reality, emphasizing the creation of highly skilled science and technology jobs to enhance the domestic supply chain for medications.
AstraZeneca is not alone in this trend; Eli Lilly is also planning a $27 billion investment in U.S. manufacturing.
Part of AstraZeneca’s investment will bolster the R&D facility in Gaithersburg, Maryland, with additional expansions of manufacturing capabilities in Maryland, California, and Texas, increasing production levels in Mount Vernon, Indiana. The aim includes enhancing research and development for new drugs, among other initiatives.
Commerce Secretary Howard Lutnick praised AstraZeneca’s decision, highlighting the significant job creation and the importance of producing more medications domestically.
Last November, AstraZeneca made a $3.5 billion capital investment focusing on R&D and manufacturing. This included $2 billion dedicated to new projects that would create over 1,000 skilled jobs in the U.S.
Recently, they opened a $300 million cell therapy manufacturing plant in Maryland that utilizes CAR-T cell therapy for treating certain cancers, adding to their extensive investment in the region.
Currently, the U.S. is AstraZeneca’s largest market, accounting for approximately 42% of its overall revenue, with goals to increase that to 50% by 2030. The company employs around 18,000 people in the U.S. and supports 92,000 jobs across the country, where it operates 19 R&D, manufacturing, and commercial sites.
AstraZeneca has contributed an estimated $5 billion directly to the U.S. economy, resulting in about $2 billion in overall economic value.
This recent announcement marks yet another investment in the U.S. made during the Trump administration. Other pharmaceutical companies, such as Bristol Myers Squibb, Roche, and Johnson & Johnson, have also declared plans to invest billions in the U.S. for R&D and manufacturing expansions.
